β受体阻滞剂治疗慢性心力衰竭的临床观察

目的观察慢性充血性心力衰竭在常规抗心衰治疗基础上，加用非选择性β受体阻滞剂（卡维地洛）115床疗效。方法选择CHF病人80例，随机分为两组，对照组39例，常规抗心衰治疗（强心、利尿、扩血管＋血管紧张素转换酶抑制剂ACEI或血管紧张素Ⅱ受体拮抗剂；观察组41例，在常规抗心衰治疗基础上，加用卡维地洛，观察4周，随访18个月。前后对比心功能、血压、心率、左室收缩末内径、左室射血分数、脑利钠肽前体、高敏C反应蛋白的变化。结果治疗组心功能明显改善，再住院率下降，治疗组与对照组疗效有显著性差异（P〈0．05）。结论CHF患者，在抗心衰基础上，常规加用β受体阻滞剂是一种安全、有效的方法。

Clinical Observation of β Receptor Blocker in Treating Congestive Heart Failure

Objective To observe the curative effects of carvedilol in treating congestive heart failure. Methods 80 patients with congestive heart failure were randomly divided into two groups. The control group （39 cases） received the routine treatment while the treatment group （41cases） received the routine treatment plus Carvedilol. Results After 4 weeks hospitalization,all patients received 18 months＇ follow-up. There were differences in the blood pressure, heart rate, left ventricular end-diastolic dimension,brain natriuretic peptide,high sensitive cross-reacting protein （P 〈 0.05）. The left ventricular ejection fraction in the treatment group was significant higher than that in the control group （P〈 0.05）. The rehospitalization rate in the treatment group was lower than that in the control group（P〈0.05）. Conclusion Carvedilol is an effective medicine in treating congestive heart failure.